North America Genotyping Market Growth Driven by Rising Use in Diagnosing Genetic and Rare Diseases
The North America genotyping market was valued at US$ 12,044.57 million in 2023 and is projected to reach US$ 62,900.63 million by 2031, expanding at a remarkable CAGR of 23.0% from 2023 to 2031.
The rising burden of genetic and rare diseases is fueling this growth. According to the World Health Organization (WHO), cancer cases are expected to surge to nearly 35 million by 2050—a 77% jump from 20 million cases recorded in 2022. Similarly, the Alzheimer’s Association reported in 2022 that more than 6 million Americans are living with Alzheimer’s disease, including 6.5 million people aged 65 and older, with nearly three-quarters aged 75 or above. Additionally, a study published in the Journal of Health Monitoring estimates that up to 300 million people worldwide are affected by rare diseases. Though individually uncommon, these conditions collectively present a formidable challenge to healthcare systems globally.
📚Download Full PDF Sample Copy of Market Report @
https://www.businessmarketinsights.com/sample/BMIRE00025971
Given the complexity of diagnosing cancer, Alzheimer’s, and rare diseases through traditional clinical methods, genotyping has emerged as an essential diagnostic tool. By analyzing DNA sequences, genotyping enables the detection of genetic variations by comparing patient samples with reference sequences. This technique is particularly effective in identifying single-nucleotide polymorphisms (SNPs)—the most common type of genetic variation, with approximately 660 million SNPs found in the human genome.
Through genome-wide association studies (GWAS), researchers can compare SNP patterns in healthy and diseased populations, revealing genetic links to common diseases and uncovering their underlying molecular mechanisms. Beyond human health, SNP genotyping plays a crucial role in differentiating strains of microorganisms, including identifying antibiotic-resistant bacteria. This capability is transforming both pharmaceutical research and clinical diagnostics and is becoming an important tool in tracking infectious disease outbreaks.
North America Genotyping Market Overview
The North America genotyping market is divided into the US, Canada, and Mexico. Market growth in this region is driven by the rising adoption of advanced technologies and solutions, along with a surge in research and development activities. Additionally, government initiatives such as the “All of Us Research Program,” efforts by genomic communities, and growing awareness of genotyping services are key factors fueling the market’s expansion across North America.
Strategic Insights for the North America Genotyping Market
Strategic insights into the North America genotyping market deliver a data-backed examination of the evolving industry landscape, spotlighting emerging trends, leading players, and distinct regional characteristics. These insights translate into actionable strategies, allowing businesses to carve out competitive advantages by uncovering underserved segments or crafting distinctive value propositions. By harnessing advanced data analytics, stakeholders — from investors to manufacturers — can stay ahead of shifting market dynamics and capitalize on new opportunities. A forward-looking approach is key, enabling players to adapt proactively and secure long-term growth in this fast-moving sector. Ultimately, these strategic insights equip decision-makers with the intelligence needed to optimize profitability and accomplish their goals within the genotyping market.
Market leaders and key company profiles
Hoffmann-La Roche Ltd.
QIAGEN NV.
Merck KGaA.
Thermo Fisher Scientific Inc.
BioTek Instruments, Inc.
TRIMGEN CORPORATION.
Illumina Inc.
Danaher Corp.
Bio-Rad Laboratories Inc.
GE HealthCare Technologies Inc.
North America Genotyping Regional Insights
The geographic scope of the North America Genotyping refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
North America Genotyping Market Segmentation
The North America genotyping market is segmented by product type, technology, application, end user, and country.
- By Product Type:
The market is divided into instruments, reagents and kits, bioinformatics, and genotyping services. Among these, the reagents and kits segment accounted for the largest market share in 2023. - By Technology:
Segmentation by technology includes microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF), and other technologies. The PCR segment emerged as the market leader in 2023. - By Application:
The market is categorized into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and other applications. In 2023, diagnostics and personalized medicine held the largest share of the market. - By End User:
End users in the market include pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and other end users. Pharmaceutical and biopharmaceutical companies led the market in terms of share in 2023. - By Country:
Geographically, the market is segmented into the US, Canada, and Mexico. The US dominated the North America genotyping market in 2023.
Key Players:
Leading companies operating in this market include Hoffmann-La Roche Ltd, QIAGEN NV, Merck KGaA, Thermo Fisher Scientific Inc, BioTek Instruments Inc, TRIMGEN CORPORATION, Illumina Inc, Danaher Corp, Bio-Rad Laboratories Inc, GE HealthCare Technologies Inc, Standard BioTools Inc, Laboratory Corp of America Holdings, Beckman Coulter Inc, BGI, Takara Bio Inc, and DiaSorin SpA.
Can you see this our reports
Europe Natural Food Colors Market – https://postyourarticle.com/europe-natural-food-colors-market-trends-size-segment-and-growth-by-forecast-to-2030-3/
North America Heavy Construction Equipment Market – https://github.com/businessmarketinsights985/business-market-insights/issues/37
Europe Plant Extracts Market – https://findit.com/uwttwdjttmkjdpa/RightNow/europe-plant-extractsmarkettrends-sizes/569cfe97-4dc7-4370-9d87-97919164ed82
Europe Machine Condition Monitoring Market – https://businessmarketins02.blogspot.com/2025/05/europe-machine-condition-monitoring.html
Europe Heat Exchanger Market – https://sites.google.com/view/businessmarketinsights145/home
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
Author’s Bio
Akshay
Senior Market Research Expert at Business Market Insights
